Top Markets
Coin of the day
Lumosa Therapeutics Co., Ltd. Lumosa Therapeutics Co., Ltd.

Lumosa Therapeutics Co., Ltd.

6535
Rangering i aksjer #14760
Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company,... Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company, headquartered in Taiwan, focused on developing innovative therapies for neurological and oncological diseases. Its most advanced product, LT-1001, an injectable analgesic, has completed Phase III clinical trials for the management of severe post-operative pain. The company's pipeline also includes LT3001, currently in Phase II for treating acute ischemic stroke; LT5001, which has finished Phase Ib trials for uremic pruritus; and LT2003, an oncology drug candidate in its preclinical development stage. Founded in 2000, Lumosa Therapeutics maintains its operational base in Taipei.
Aksjekurs
$2.35
Markedsverdi
$394.12M
Endring (1 dag)
-1.07%
Endring (1 år)
-64.75%
Land
TW
Handel Lumosa Therapeutics Co., Ltd. (6535)

Kategori

EPS for Lumosa Therapeutics Co., Ltd. (6535)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Lumosa Therapeutics Co., Ltd. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Lumosa Therapeutics Co., Ltd. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH